MINNEAPOLIS, March 25, 2020 /PRNewswire/ -- Bio-Techne
Corporation (NASDAQ:TECH) today shared news from clinical partners
on the use of the ProteinSimple™-branded
Ella™ Automated Immunoassay platform in the fight
against COVID-19.
In a March 23, 2020 press release,
the Icahn School of Medicine, Mount Sinai announced that they are
utilizing Bio-Techne's Ella Automated Immunoassay Platform to
monitor individual immune responses to COVID-19. Specifically, the
Ella Cytokine Storm Panel is being used to detect Cytokine Release
Syndrome (CRS) in real-time. Cytokine Release Syndrome represents a
critical point in individuals with severe COVID-19 disease where
immune molecules, called cytokines, attack the patient's organs,
representing a critical and potentially fatal point in disease
management.
As stated in its press release, "Mount Sinai clinical
laboratories will use the ELLA Cytokine Storm Panel in COVID-19
patients who have been admitted to the hospital to monitor them and
know, in real time, when they are experiencing cytokine storm. The
test results are available in a few hours and can be repeated
throughout the course of care to help guide hospital care and to
measure the response to experimental drugs given in clinical trials
for COVID-19 patients." (link) "Mount Sinai clinical laboratories
will use the ELLA Cytokine Storm Panel in COVID-19 patients who
have been admitted to the hospital to monitor them and know, in
real time, when they are experiencing cytokine storm. The test
results are available in a few hours and can be repeated throughout
the course of care to help guide hospital care and to measure the
response to experimental drugs given in clinical trials for
COVID-19 patients."
Mount Sinai joins hospitals in Italy and throughout Europe that have and are continuing to adopt
the Ella platform for CRS testing during this crisis. Ella's
sensitivity, simplified workflow, and fast time-to-results make the
platform ideal for CRS testing and are the key factors driving this
adoption. These developments follow the 2018 announcement that
Micropoint Biotechnologies of China is developing clinical applications for
the detection of CRS on the Ella platform.
"Ella is a potentially important tool for monitoring and saving
patients who are infected by COVID-19," commented Chuck Kummeth, President and Chief Executive
Officer of Bio-Techne. "The Ella Cytokine Storm Panel has the
potential to enable front line healthcare workers to triage
high-risk COVID-19 patients in real-time, guide hospital care and
to measure responses to experimental clinical trial drugs. Ella
joins several other products Bio-Techne has deployed to combat
COVID-19, including RNAscope™ for detection of coronavirus in
tissue and antibodies for vaccine development. We are focused on
leveraging our deep portfolio and developing new tools to enable
solutions for this rapidly evolving pandemic."
Bio-Techne aims to further enable customers to utilize the Ella
platform for this and other clinical applications where
time-to-results is critical. To that end, Bio-Techne is
investing in both near-term and long-term efforts to enable broader
clinical adoption of Ella and expand beyond its current Research
Use Only (RUO) status. This includes partnering with clinical
research customers to pursue Emergency Use Authorization (EUA)
status for COVID-19 testing in key regions, as well as investing in
manufacturing and quality control systems required for diagnostic
products.
About Bio-Techne Corporation (NASDAQ: TECH)
Ella Automated Immunoassay platform, ProteinSimple, a Bio-Techne
Brand
Contact: David Clair, Senior
Director, Business Development
david.clair@bio-techne.com
612-656-4416
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bio-technes-ella-on-the-front-lines-in-fight-against-covid-19-301029692.html
SOURCE Bio-Techne Corporation